TriSalus Life Sciences, Inc.
NASDAQ: TLSI0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Mary T. Szela
- Employees
- 110
- Headquarters
- Westminster, United States
- IPO year
- 2021
- Market cap
- $157.7M
- Website
- https://trisaluslifesci.com
Loading TLSI…
Loading profile data…Frequently asked questions about TLSI
What does TriSalus Life Sciences, Inc. (TLSI) do?
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tu...
Where does TLSI trade?
TriSalus Life Sciences, Inc. (TLSI) trades on the NASDAQ Global Market.
What sector is TLSI in?
TriSalus Life Sciences, Inc. (TLSI) operates in the Healthcare sector, specifically in the Medical - Devices industry.
Who is the CEO of TriSalus Life Sciences, Inc.?
Mary T. Szela is the chief executive officer of TriSalus Life Sciences, Inc. (TLSI).
Where is TriSalus Life Sciences, Inc. headquartered?
TriSalus Life Sciences, Inc. is headquartered in United States.
Does TLSI pay a dividend?
TriSalus Life Sciences, Inc. (TLSI) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TLSI go public?
TriSalus Life Sciences, Inc. (TLSI) completed its initial public offering in 2021.